Influenza Medication Market
The global influenza medication market is primarily driven by annual epidemic outbreak in developed countries such as the U.S. and flu outbreaks in several regions across the globe.
As per a report published by Centers for Disease Control and Prevention (CDC), in October 2019, 9.7 million cases of influenza had been reported in the U.S. in that particular year.
Global influenza medication market include application of seasonal vaccines. However, in several cases, the flu vaccines may not be efficient for prevention.
The influenza medication market is influenced by several drivers and trends. These factor may bring momentum to demand rate for influenza (flu) antiviral drugs.
Further, rising awareness regarding serious impacts of influenza is one of the key driving factors driving growth of the global influenza medication market. Impact of influenza on human health may result in some other critical diseases.
On other hand, current lifestyle trends may result in development of influenza in significant proportion of the global population. This may emerge as one of most common contagious diseases.
Pregnant women, geriatric population, and people with weak autoimmune system are at high risk of developing influenza. The genetic mutation nature of the virus impels them to undergo consistent change. This has adverse effect on human immunity. This has resulted in research and development of novel therapeutics method and introduction of new influenza medications. This, in turn, is likely to fuel the influenza drugs market.
Moreover, increasing healthcare expenditure and investment in research and development activities are likely to accelerate growth rate of the global influenza medication market. However, adoption of influenza vaccines is interfering with growth of the market.
Global Influenza Medication Market: Snapshot
Influenza medication includes antiviral drugs prescribed for the treatment of influenza. Influenza, also known as flu, is a respiratory disease caused by an influenza virus. It is a viral infectious disease that includes three major types: type A, type B, and type C. The common symptoms of the disorder are cold, cough, fever, and sore throat, which can be severe or mild. Seasonal outbreak of influenza primarily occurs in winter. Most people generally recover fully, but severe complications such as pneumonia can also develop. Initiation of antiviral treatment is recommended for hospitalized influenza patients. High growth of the global influenza medication market is due to unmet medical needs within the annual influenza epidemics along with strong R&D focus resulting in new and advanced treatments and drugs, and increasing demand due to government stockpiling.
Based on Distribution Channel, Pharmacies Held Lead however Hospitals Likely to Show Lucrative Prospects
The global influenza medications market has been classified on the basis of three categories, which are by product, distribution channel, and geography (regions & countries). The product category is further sub segmented into zanamivir, oseltamivir, peramivir, amantadine, rimantadine, inosine and others including laninamivir octanoate. Of these, oseltamivir held lead with a share of 48.8% in the global market in 2016. The rising use of oseltamivir in the treatment of flu triggered by H1N1 virus and prophylaxis is one of the key reasons behind the segment’s lead.
In term of distribution channels, global influenza medications market is divided into hospitals, clinics, pharmacies and others. Incidence and prevalence of flu are gradually increasing across the globe. Of these, the pharmacies segment held dominance in 2016. Through the course of the forecast period, growth run witnessed by the segment is likely to remain steady due to the mushrooming pharmacy stores around the world. Besides this, the market is likely to witness lucrative prospects in the hospitals segment.
For instance, According to the CDC, around 5% to 20% of the population is affected with the flu in the U.S. each year. Additionally, an estimated 200,000 people are hospitalized due to flu infection in the U.S. each year; of these 36,000 die due to flu complications. Favorable policies for treatment and prevention of influenza by the government in developed regions. These are the major drivers in the growth of influenza medication market. The market in Asia Pacific is expected to expand at a high CAGR of 1.8% during the forecast period due to availability of low cost treatment and availability of better health care facilities. Patent expiry of key drugs and entry of generics and Side effects of anti-influenza drug therapy are the major restraining factors affecting Influenza medication market.
US Emerged as Most Attractive Market for Influenza Medication in North America
By geography, global Influenza medication market has been segmented into major five regions: North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In 2016, North America and Europe accounted for the largest share of the Influenza medication market followed by Asia, Latin America, and Middle East & Africa. The U.S. dominated the Influenza medication market in North America, accounting for around 49.8% share in 2016. North America leads the global market with a major contribution of the U.S. owing to increasing adoption of advanced and high-cost drug therapies, increased treatment rate, and favorable reimbursement policies in the country. Europe and Asia Pacific are projected to be moderately lucrative markets from 2017 to 2025. Increase in the number of public awareness programs for prevention and diagnosis of chronic diseases such as influenza has significantly reduced the prevalence of influenza in Europe. In Europe, demand for influenza medication products is the maximum, with a major share held by the inosine product segment. Asia Pacific is expected to dominate the global market, due to major contribution from developing countries. China and India are highly populated countries with the maximum number of influenza patients making them major contributor to the growth of the market in Asia Pacific.
The key players operating in the global influenza medications market are Daiichi Sankyo Company, GlaxoSmithKline plc, Natco Pharma, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (Novartis AG), Sun Pharmaceutical Industries Ltd. and Mylan, Inc. The global Influenza medication market is dominated only by few players that operates in global market.
The global influenza medication market is segmented as follows:
|
Product |
|
|
Distribution channel |
|
|
Geography |
|
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Research Methodology
3. Executive Summary
3.1. Global Influenza Medication Market Snapshot
4. Market Overview
4.1. Product Overview
4.2. Key Industry Events
4.3. Global Influenza Medication Market Size (US$ Mn) Forecast, 2015-2025
4.4. Market Opportunity Map
4.5. Porter's Five Forces Analysis
4.6. Value Chain Analysis
4.7. Global Influenza Medication Market Outlook
4.8. Major Revenue Pockets Analysis
4.9. Market Penetration Strategies
5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.2.1. Increase in prevalence and incidence of influenza
5.2.2. Strong R&D focus resulting in new and advanced treatments and drugs
5.2.3. Fast acceptance by physicians and drug formularies
5.2.4. Outbreak of pandemic influenza
5.2.5. for treatment and prevention of influenza
5.2.6. Increasing government expenditure on health care
5.3. Restraints
5.3.1. High cost of drug development
5.3.2. Side effects of antiviral therapy
5.4. Opportunities
5.4.1. Product development through partnerships
5.4.2. Alternative mechanisms that might have higher efficacy and fewer side effects
6. Global Influenza Medication Market Analysis, by Product
6.1. Introduction
6.2. Key Findings
6.3. Global Influenza Medication Market Value Share Analysis, by Product
6.4. Global Influenza Medication Market Forecast, by Product
6.4.1. Zanamivir
6.4.2. Oseltamivir
6.4.3. Peramivir
6.4.4. Amantadine
6.4.5. Rimantadine
6.4.6. Inosine
6.4.7. Other (Laninamivir Octanoate, etc.)
6.5. Global Influenza Medication Market Analysis, by Product
6.6. Global Influenza Medication Market Attractiveness Analysis, by Product
7. Global Influenza Medication Market Analysis, by Distribution Channel
7.1. Introduction
7.2. Key Findings
7.3. Global Influenza Medication Market Value Share Analysis, by Distribution Channel
7.4. Global Influenza Medication Market Forecast, by Distribution Channel
7.4.1. Hospitals
7.4.2. Clinics
7.4.3. Pharmacies
7.4.4. Others
7.5. Global Influenza Medication Market Analysis, by Distribution Channel
7.6. Global Influenza Medication Market Attractiveness Analysis, by Distribution Channel
8. Global Influenza Medication Market Analysis, by Region
8.1. Global Market Scenario by Country
8.2. Global Influenza Medication Market Value Share Analysis, by Region
8.3. Global Influenza Medication Market Forecast, by Region
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Latin America
8.3.5. Middle East & Africa
8.4. Global Influenza Medication Market Attractiveness Analysis, by Region
9. North America Influenza Medication Market Analysis
9.1. Key Findings
9.2. North America Influenza Medication Market Overview
9.3. North America Influenza Medication Market Value Share Analysis, by Country
9.4. North America Influenza Medication Market Forecast, by Country
9.4.1. U.S.
9.4.2. Canada
9.5. North America Influenza Medication Market Value Share Analysis, by Product
9.6. North America Influenza Medication Market Value Share Analysis, by Product
9.7. North America Influenza Medication Market Forecast, by Product
9.8. North America Influenza Medication Market Value Share Analysis, by Distribution Channel
9.9. North America Influenza Medication Market Forecast, by Distribution Channel
9.10. North America Influenza Medication Market Attractiveness Analysis
9.11. Key Trends
10. Europe Influenza Medication Market Analysis
10.1. Key Findings
10.2. Europe Influenza Medication Market Overview
10.3. Europe Influenza Medication Market Value Share Analysis, by Country
10.4. Europe Influenza Medication Market Forecast, by Country
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Poland
10.4.7. Rest of the Europe
10.5. Europe Influenza Medication Market Value Share Analysis, by Product
10.6. Europe Influenza Medication Market Value Share Analysis, by Product
10.7. Europe Influenza Medication Market Forecast, by Product
10.8. Europe Influenza Medication Market Value Share Analysis, by Distribution Channel
10.9. Europe Influenza Medication Market Forecast, by Distribution Channel
10.10. Europe Influenza Medication Market Attractiveness Analysis
10.11. Key Trends
11. Asia Pacific Influenza Medication Market Analysis
11.1. Key Findings
11.2. Asia Pacific Influenza Medication Market Overview
11.3. Asia Pacific Influenza Medication Market Value Share Analysis, by Country
11.4. Asia Pacific Influenza Medication Market Forecast, by Country
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. South Korea
11.4.6. Rest of Asia Pacific
11.5. Asia Pacific Influenza Medication Market Value Share Analysis, by Product
11.6. Asia Pacific Influenza Medication Market Value Share Analysis, by Product
11.7. Asia Pacific Influenza Medication Market Forecast, by Product
11.8. Asia Pacific Influenza Medication Market Value Share Analysis, by Distribution Channel
11.9. Asia Pacific Influenza Medication Market Forecast, by Distribution Channel
11.10. Asia Pacific Influenza Medication Market Attractiveness Analysis
11.11. Key Trends
12. Latin America Influenza Medication Market Analysis
12.1. Key Findings
12.2. Latin America Influenza Medication Market Overview
12.3. Latin America Influenza Medication Market Value Share Analysis, by Country
12.4. Latin America Influenza Medication Market Forecast, by Country
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Influenza Medication Market Value Share Analysis, by Product
12.6. Latin America Influenza Medication Market Value Share Analysis, by Product
12.7. Latin America Influenza Medication Market Forecast, by Product
12.8. Latin America Influenza Medication Market Value Share Analysis, by Distribution Channel
12.9. Latin America Influenza Medication Market Forecast, by Distribution Channel
12.10. Rest of World Influenza Medication Market Attractiveness Analysis
12.11. Key Trends
13. Middle East and Africa Influenza Medication Market Analysis
13.1. Key Findings
13.2. Middle East and Africa Influenza Medication Market Overview
13.3. Middle East and Africa Influenza Medication Market Value Share Analysis, by Country
13.4. Middle East and Africa Influenza Medication Market Forecast, by Country
13.4.1. South Africa
13.4.2. Saudi Arabia
13.4.3. UAE
13.4.4. Rest of Middle East & Africa
13.5. Middle East and Africa Influenza Medication Market Value Share Analysis, by Product
13.6. Middle East and Africa Influenza Medication Market Value Share Analysis, by Product
13.7. Middle East and Africa Influenza Medication Market Forecast, by Product
13.8. Middle East and Africa Influenza Medication Market Value Share Analysis, by Distribution Channel
13.9. Middle East and Africa Influenza Medication Market Forecast, by Distribution Channel
13.10. Middle East and Africa Influenza Medication Market Attractiveness Analysis
13.11. Key Trends
14. Competition Landscape
14.1. Competition Matrix
14.2. Company Profiles
14.2.1. F. Hoffmann-La Roche Ltd.
14.2.1.1. Company Details
14.2.1.2. Business Overview
14.2.1.3. Financial Overview
14.2.1.4. Strategic Overview
14.2.1.5. SWOT Analysis
14.2.2. Teva Pharmaceutical Industries Ltd.
14.2.2.1. Company Details
14.2.2.2. Business Overview
14.2.2.3. Financial Overview
14.2.2.4. Strategic Overview
14.2.2.5. SWOT Analysis
14.2.3. Sandoz International GmbH (Novartis AG)
14.2.3.1. Company Details
14.2.3.2. Business Overview
14.2.3.3. Financial Overview
14.2.3.4. Strategic Overview
14.2.3.5. SWOT Analysis
14.2.4. Sun Pharmaceutical Industries Ltd.
14.2.4.1. Company Details
14.2.4.2. Business Overview
14.2.4.3. Financial Overview
14.2.4.4. Strategic Overview
14.2.4.5. SWOT Analysis
14.2.5. Mylan, Inc.
14.2.5.1. Company Details
14.2.5.2. Business Overview
14.2.5.3. Financial Overview
14.2.5.4. Strategic Overview
14.2.5.5. SWOT Analysis
14.2.6. GlaxoSmithKline plc
14.2.6.1. Company Details
14.2.6.2. Business Overview
14.2.6.3. Financial Overview
14.2.6.4. Strategic Overview
14.2.6.5. SWOT Analysis
14.2.7. Daiichi Sankyo Company
14.2.7.1. Company Details
14.2.7.2. Business Overview
14.2.7.3. Financial Overview
14.2.7.4. Strategic Overview
14.2.7.5. SWOT Analysis
14.2.8. Natco Pharma
14.2.8.1. Company Details
14.2.8.2. Business Overview
14.2.8.3. Financial Overview
14.2.8.4. Strategic Overview
14.2.8.5. SWOT Analysis
List of Tables
Table 01: Global Influenza Medication Market Size (US$ Mn) Forecast, by Product, 2015–2025
Table 02: Global Influenza Medication Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 03: Global Influenza Medication Market Revenue (US$ Mn) Forecast, by Region, 2015–2025
Table 04: North America Influenza Medication Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 05: North America Influenza Medication Market Size (US$ Mn) Forecast, by Product, 2015–2025
Table 06: North America Influenza Medication Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 07: Europe Influenza Medication Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 08: Europe Influenza Medication Market Size (US$ Mn) Forecast, by Product, 2015–2025
Table 09: Europe Influenza Medication Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 10: Asia Pacific Influenza Medication Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 11: Asia Pacific Influenza Medication Market Size (US$ Mn) Forecast, by Product, 2015–2025
Table 12: Asia Pacific Influenza Medication Market Size (US$ Mn) Forecast, by Distribution Channels, 2015–2025
Table 13: Latin America Influenza Medication Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 14: Latin America Influenza Medication Market Size (US$ Mn) Forecast, by Product, 2015–2025
Table 15: Latin America Influenza Medication Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 16: Middle East & Africa Influenza Medication Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 17: Middle East & Africa Influenza Medication Market Size (US$ Mn) Forecast, by Product, 2015–2025
Table 18: Middle East & Africa Influenza Medication Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
List of Figures
Figure 01: Global Influenza Medications Market Snapshot
Figure 02: Global Influenza Medication Market Size (US$ Mn) Forecast, 2015–2025
Figure 04: Market Value Share, by Distribution Channels (2016)
Figure 03: Market Value Share, by Product (2016)
Figure 05: Market Value Share, by Region (2016)
Figure 06: Illustration of the Pharmaceutical Price Build-up
Figure 07: Global Influenza Medication Market Value Share Analysis, by Product, 2016 and 2025
Figure 08: Global Influenza Medication Market Value (US$ Mn) and Y-o-Y Growth, by Zanamivir, 2015–2025
Figure 09: Global Influenza Medication Market Value (US$ Mn) and Y-o-Y Growth, by Oseltamivir, 2015–2025
Figure 10: Global Influenza Medication Market Value (US$ Mn) and Y-o-Y Growth, by Peramivir, 2015–2025
Figure 11: Global Influenza Medication Market Value (US$ Mn) and Y-o-Y Growth, by Amantadine, 2015–2025
Figure 12: Global Influenza Medication Market Value (US$ Mn) and Y-o-Y Growth, by Rimantadine, 2015–2025
Figure 13: Global Influenza Medication Market Value (US$ Mn) and Y-o-Y Growth, by Inosine, 2015–2025
Figure 14: Global Influenza Medication Market Value (US$ Mn) and Y-o-Y Growth, by Other (Laninamivir Octanoate, etc.), 2015–2025
Figure 15: Global Influenza Medication Market Attractiveness Analysis, by Product, 2015–2025
Figure 16: Global Influenza Medication Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 17: Global Influenza Medication Market Value (US$ Mn) and Y-o-Y Growth, by Hospitals, 2015–2025
Figure 18: Global Influenza Medication Market Value (US$ Mn) and Y-o-Y Growth, by Clinics, 2015–2025
Figure 19: Global Influenza Medication Market Value (US$ Mn) and Y-o-Y Growth, by Pharmacies, 2015–2025
Figure 20: Global Influenza Medication Market Value (US$ Mn) and Y-o-Y Growth, by Others, 2015–2025
Figure 21: Global Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2015–2025
Figure 22: Global Influenza Medication Market Value Share Analysis, by Region, 2016 and 2025
Figure 23: Global Influenza Medication Market Attractiveness Analysis, by Region, 2017–2025
Figure 24: North America Influenza Medication Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
Figure 25: North America Influenza Medication Market Attractiveness Analysis, by Country, 2017–2025
Figure 26: North America Influenza Medication Market Value Share Analysis, by Country, 2016 and 2025
Figure 27: North America Influenza Medication Market Value Share Analysis, by Product, 2016 and 2025
Figure 28: North America Influenza Medication Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 29: North America Influenza Medication Market Attractiveness Analysis, by Product, 2015–2025
Figure 30: North America Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2015–2025
Figure 31: Europe Influenza Medication Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
Figure 32: Europe Influenza Medication Market Attractiveness Analysis, by Country, 2017–2025
Figure 33: Europe Influenza Medication Market Value Share Analysis, by Country, 2016 and 2025
Figure 34: Europe Influenza Medication Market Value Share Analysis, by Product, 2016 and 2025
Figure 35: Europe Influenza Medication Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 36: Europe Influenza Medication Market Attractiveness Analysis, by Product, 2015–2025
Figure 37: Europe Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2015–2025
Figure 38: Asia Pacific Influenza Medication Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
Figure 39: Asia Pacific Influenza Medication Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
Figure 40: Asia Pacific Influenza Medication Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 41: Asia Pacific Influenza Medication Market Value Share Analysis, by Product, 2016 and 2025
Figure 42: Asia Pacific Influenza Medication Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 43: Asia Pacific Influenza Medication Market Attractiveness Analysis, by Product, 2015–2025
Figure 44: Asia Pacific Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2015–2025
Figure 45: Latin America Influenza Medication Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 46: Latin America Influenza Medication Market Attractiveness Analysis, by Country, 2017–2025
Figure 47: Latin America Influenza Medication Market Value Share Analysis, by Country, 2016 and 2025
Figure 48: Latin America Influenza Medication Market Value Share Analysis, by Product, 2016 and 2025
Figure 49: Latin America Influenza Medication Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 50: Latin America Influenza Medication Market Attractiveness Analysis, by Product, 2015–2025
Figure 51: Latin America Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2015–2025
Figure 52: Middle East & Africa Influenza Medication Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 53: Middle East & Africa Influenza Medication Market Attractiveness Analysis, by Country, 2017–2025
Figure 54: Middle East & Africa Influenza Medication Market Value Share Analysis, by Country, 2016 and 2025
Figure 55: Middle East & Africa Influenza Medication Market Value Share Analysis, by Product, 2016 and 2025
Figure 56: Middle East & Africa Influenza Medication Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 57: Middle East & Africa Influenza Medication Market Attractiveness Analysis, by Product, 2015–2025
Figure 58: Middle East & Africa Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2015–2025
Figure 59: Global Influenza Medication Market Share Analysis, by Company, 2016 (Estimated)
Figure 60: F. Hoffmann-La Roche Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016rv
Figure 61: F. Hoffmann-La Roche Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 62: F. Hoffmann-La Roche Ltd. Breakdown of Net Sales, by Region (Pharmaceutical Segment), 2016
Figure 63: F. Hoffmann-La Roche Ltd. Breakdown of Net Sales (Overall Company Level), 2016
Figure 64: Teva Pharmaceutical Industries Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 65: Teva Pharmaceutical Industries Ltd. R&D Intensity and Sales & Marketing Intensity (%) – Company Level or Segment Level, 2015–2016
Figure 66: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region, 2016
Figure 67: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales (Overall Company Level), 2016
Figure 68: Sandoz International GmbH (Novartis AG) Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 69: Sandoz International GmbH (Novartis AG) R&D Intensity and Sales & Marketing Intensity (%) – Company Level or Segment Level, 2013–2016
Figure 70: Sandoz International GmbH (Novartis AG) Breakdown of Net Sales, by Region, 2016
Figure 71: Sandoz International GmbH (Novartis AG) Breakdown of Net Sales (Overall Company Level), 2016
Figure 72: Sun Pharmaceutical Industries Ltd. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 73: Sun Pharmaceutical Industries Ltd. R&D Intensity and Sales and Marketing Intensity (%) – Company Level or Segment Level, 2015–2016
Figure 74: Sun Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region (overall company), 2016
Figure 75: Sun Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Business Segment, 2016
Figure 76: Mylan, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 77: Mylan, Inc. R&D Intensity and Sales and Marketing Intensity (%) – Company Level or Segment Level, 2015–2016
Figure 78: Mylan, Inc. Breakdown of Net Sales, by Region (overall company), 2016
Figure 79: GlaxoSmithKline plc Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 80: GlaxoSmithKline plc R&D Intensity (%), 2015–2016
Figure 81: GlaxoSmithKline plc Breakdown of Net Sales, by Region, 2016
Figure 82: GlaxoSmithKline plc Breakdown of Net Sales, by Segment, 2016
Figure 83: Daiichi Sankyo Company Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 84: Daiichi Sankyo Company R&D Intensity (%), 2015–2016
Figure 85: Daiichi Sankyo Company Breakdown of Net Sales, by Region, 2016
Figure 86: Natco Pharma Net Sales Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 87: Natco Pharma R&D Intensity (%), 2015–2016
Figure 88: Natco Pharma Breakdown of Net Sales, by Segment 2017
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
*86 figures and 60 tables includes